<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1618575</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2025.1618575</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Investigating the molecular mechanisms of the &#x201c;Astragalus-Codonopsis&#x201d; herb pair in treating diabetes: a network pharmacology and bioinformatics approach with molecular docking validation</article-title>
<alt-title alt-title-type="left-running-head">Yang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2025.1618575">10.3389/fbioe.2025.1618575</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yang</surname>
<given-names>Jinliang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Mingyang</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhu</surname>
<given-names>Ziyue</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Fengling</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Yanyan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hou</surname>
<given-names>Jinbo</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Qingfeng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yuan</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>XiuMei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3047942/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Traditional Chinese Medicine</institution>, <institution>General Hospital of Ningxia Medical University</institution>, <addr-line>Yinchuan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Pharmacy</institution>, <institution>Ningxia Medical University</institution>, <addr-line>Yinchuan</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>College of Life Science and Technology</institution>, <institution>China Pharmaceutical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Dermatology, Lingwu People&#x2019;s Hospital</institution>, <addr-line>Lingwu</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>School of Information Science and Engineering</institution>, <institution>Henan University of Technology</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2836233/overview">Zhi Chen</ext-link>, Korea University, Republic of Korea</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2235218/overview">Sagnik Nag</ext-link>, Monash University Malaysia, Malaysia</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3054941/overview">Long-gao Xiao</ext-link>, Chinese Academy of Sciences (CAS), China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3055012/overview">Yifan Ouyang</ext-link>, Ningde Normal University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Hui Yuan, <email>19995104086@163.com</email>; XiuMei Li, <email>wqnlxm@163.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1618575</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Yang, Li, Zhu, Han, Ma, Hou, Zhao, Yuan and Li.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Yang, Li, Zhu, Han, Ma, Hou, Zhao, Yuan and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Astragalus membranaceus and Codonopsis pilosula are widely used in traditional chinese medicine for the treatment of diabetes because of their notable hypoglycemic pharmacological effects. Studies have indicatedthat the active compounds in the Astragalus-Codonopsis herb pair may exert their hypoglycemic effects through the modulation of the insulin receptor (IRSP) signaling pathway. In this study, the rhamnolitrin and folic acid were confirmed as the key active components in the Astragalus-Codonopsis herb pair that regulate the IRSP, with their synergistic mechanisms in Type 2 Diabetes Mellitus (T2DM) being further systematically explored by network pharmacology combined with DFT theoretical calculation, molecular docking, molecular dynamics simulation and alanine scanning mutation technology. The results suggest that GSK3&#x3b2; is a critical target through which rhamnolitrin and folic acid exert their anti-diabetic effects. Subsequent molecular docking and molecular dynamics simulations confirmed that both active compounds selected in this study can bind stably with the GSK3&#x3b2; protein. Further alanine scanning mutagenesis experiments validated the importance of key amino acid residues in ligand-receptor interactions. Finally, DFT theoretical calculations provided a detailed elucidation of the binding mechanism between the core components (rhamnolitrin and folic acid) and the target protein GSK3&#x3b2;. This study not only revealed the molecular mechanism of Astragalus-Codonopsis for the treatment of type 2 diabetes, provided a theoretical basis for its clinical application, but also provided a potential molecular target for the development of new anti-diabetes drugs.</p>
</abstract>
<kwd-group>
<kwd>Astragalus-Codonopsis</kwd>
<kwd>network pharmacology</kwd>
<kwd>molecular dynamics</kwd>
<kwd>GSK3 &#x3b2;</kwd>
<kwd>insulin resistance</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Nanobiotechnology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>The Insulin Receptor Signaling Pathway (IRSP) is a crucial signaling pathway through which cells respond to insulin stimulation, primarily regulating glucose uptake, metabolism and storage (<xref ref-type="bibr" rid="B31">Taha and Klip, 1999</xref>; <xref ref-type="bibr" rid="B1">Cantley, 2002</xref>). Glycogen Synthase Kinase 3&#x3b2; (GSK3&#x3b2;) is a key protein kinase in the IRSP and plays a significant role in the pathogenesis of Type 2 Diabetes Mellitus (T2DM) (<xref ref-type="bibr" rid="B2">Chen et al., 2024</xref>; <xref ref-type="bibr" rid="B28">Sharma et al., 2008</xref>). Under normal physiological conditions, GSK3&#x3b2; regulates Glycogen synthesis and breakdown through Glycogen Synthase (GS) (<xref ref-type="bibr" rid="B22">Patel et al., 2008</xref>). However, in patients with type 2 diabetes, the activity of GSK3&#x3b2; is abnormally elevated, leading to excessive inhibition of GS activity, reduced glycogen synthesis, and consequently, elevated blood glucose levels, a phenomenon known as insulin resistance (<xref ref-type="bibr" rid="B38">Xi et al., 2016</xref>; <xref ref-type="bibr" rid="B42">Zhang et al., 2014</xref>). Therefore, inhibition of GSK3&#x3b2; activity to modulate insulin resistance has become one of the important strategies for treating Type 2 Diabetes.</p>
<p>Astragalus membranaceus and Codonopsis pilosula, as traditional herbal medicines, have a long history and wide application in the treatment of diabetes and its complications (<xref ref-type="bibr" rid="B9">Hong et al., 2024</xref>; <xref ref-type="bibr" rid="B21">Mao et al., 2022</xref>). Modern pharmacological studies have demonstrated that Astragalus-Codonopsis herb pair exhibits significant hypoglycemic effects, potentially through mechanisms such as modulating insulin resistance, improving pancreatic &#x3b2;-cell function, and inhibiting inflammation (<xref ref-type="bibr" rid="B45">Zheng et al., 2020</xref>; <xref ref-type="bibr" rid="B16">Lan et al., 2023</xref>). Astragalus polysaccharides, as the core active component of Astragalus, have anti-diabetic effects. Relevant studies have shown that the improvement of insulin resistance and islet cell function by astragalus polysaccharides may be the potential mechanisms for the treatment of diabetes (<xref ref-type="bibr" rid="B15">Ke et al., 2017</xref>; <xref ref-type="bibr" rid="B39">Yang et al., 2020</xref>). Among them, rhamnocitrin and folic acid are considered to be the core active ingredients in Astragalus-Codonopsis pairs, which have potential anti-diabetic effects (<xref ref-type="bibr" rid="B5">El-Khodary et al., 2022</xref>). The relevant research evidence suggests that the antioxidant effect of scavenging free radicals from rhamnocitrin may be a potential therapeutic mechanism for diabetes management (<xref ref-type="bibr" rid="B12">Jiang et al., 2008</xref>; <xref ref-type="bibr" rid="B11">Jiang et al., 2009</xref>; <xref ref-type="bibr" rid="B34">Tu et al., 2007</xref>; <xref ref-type="bibr" rid="B41">Zhang et al., 2020</xref>). However, the molecular mechanisms by which these components collaboratively exert hypoglycemic effects, particularly their interactions with the GSK3&#x3b2; protein, have not yet been fully elucidated.</p>
<p>In recent years, the emergence of computational biology methods such as network pharmacology, molecular docking and molecular dynamics simulation has provided new approaches for revealing the mechanism of action of multi-components and multi-targets of traditional Chinese medicine (<xref ref-type="bibr" rid="B47">Dupuy et al., 2015</xref>). These technologies would enable the analysis of interactions between effective components of traditional Chinese medicines and disease-related targets at a system-wide level, and offer powerful tools for the modernization of traditional Chinese medicine (<xref ref-type="bibr" rid="B18">Li et al., 2023</xref>; <xref ref-type="bibr" rid="B23">Pinzi and Rastelli, 2019</xref>; <xref ref-type="bibr" rid="B6">Filipe and Loura, 2022</xref>). Based on this, the present study aims to systematically explore the inhibitory effects of rhamnocitrin and folic acid on GSK3&#x3b2; in the Astragalus-Codonopsis herb pair and their potential mechanisms for treating Type 2 Diabetes, employing network pharmacology, molecular docking, molecular dynamics simulations, and alanine scanning mutagenesis experiments, with the goal of providing new theoretical insights and experimental support for the modernization of traditional Chinese medicine in diabetes treatment research.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Network pharmacological study of Astragalus and Codonopsis in the treatment of T2DM</title>
<sec id="s2-1-1">
<title>2.1.1 Enrichment of potential bioactive compounds and targets in Huangqi-Dangshen</title>
<p>Based on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (<ext-link ext-link-type="uri" xlink:href="http://lspnwu.edu.cn/tcmspphp">http://lspnwu.edu.cn/tcmspphp</ext-link>), potential bioactive compounds and their corresponding targets in Huangqi and Dangshen were identified according to the criteria of oral bioavailability (OB &#x2265; 0.30) and drug-likeness index (DL &#x2265; 0.18) (<xref ref-type="bibr" rid="B26">Ru et al., 2014</xref>). The SMILES identifiers of the compounds were retrieved from the PubChem database (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>), and further exploration of potential targets not included in the TCMSP platform was conducted using Swiss Target Prediction (<ext-link ext-link-type="uri" xlink:href="http://swisstargetprediction.ch/">http://swisstargetprediction.ch/</ext-link>) (<xref ref-type="bibr" rid="B4">Daina et al., 2019</xref>). Subsequently, supplementary screening was performed using the Herb database (<ext-link ext-link-type="uri" xlink:href="http://herb.ac.cn">http://herb.ac.cn</ext-link>) based on the Lipinski&#x2019;s Rule of Five, with the following criteria: molecular weight (MW &#x2264; 500&#xa0;Da), octanol-water partition coefficient (Alg<sup>p</sup> &#x2264; 5), hydrogen bond donors (Hdon &#x2264; 5), hydrogen bond acceptors (Hacc &#x2264; 10), and rotatable bonds (RBN &#x2264;10). Next, target screening was carried out using the Batman database (<ext-link ext-link-type="uri" xlink:href="http://bionet.ncpsb.org.cn/batman-tcm/">http://bionet.ncpsb.org.cn/batman-tcm/</ext-link>) according to the following criteria: score cutoff (&#x2265;0.84), druggability score (&#x2265;0.10), and P-value (&#x2264;0.05). Finally, the selected target names were converted to standard gene symbols using the UniProt database (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link>).</p>
</sec>
<sec id="s2-1-2">
<title>2.1.2 Collection and screening of candidate targets for diabetes</title>
<p>The diabetes-related targets were collected using &#x201c;Diabetes mellitus type 2&#x201d; and &#x201c;diabetes&#x201d; as keywords through GeneCards (<ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link>), Therapeutic Target Database (<ext-link ext-link-type="uri" xlink:href="https://idrblab.org/ttd">https://idrblab.org/ttd</ext-link>), the Human Mendelian Inheritance Database (<ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>), and the Disgenet database (<ext-link ext-link-type="uri" xlink:href="http://www.disgenet.org/">http://www.disgenet.org/</ext-link>) (<xref ref-type="bibr" rid="B46">Zhou et al., 2024</xref>). Therapeutic Target Database (<ext-link ext-link-type="uri" xlink:href="https://idrblab.org/ttd">https://idrblab.org/ttd</ext-link>), the Human Mendelian Inheritance Database (<ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>), and the Disgenet database (<ext-link ext-link-type="uri" xlink:href="http://www.disgenet.org/">http://www.disgenet.org/</ext-link>).</p>
</sec>
<sec id="s2-1-3">
<title>2.1.3 Construction of the drug-compound-intersection target regulatory network and identification of core targets</title>
<p>A Venn diagram was constructed using the online tool Draw Venn Diagram (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.psb.ugent.be">http://bioinformatics.psb.ugent.be</ext-link>) to identify the intersection targets between the drug and diabetes. The identified intersection targets were then imported into the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (<xref ref-type="bibr" rid="B30">Szklarczyk et al., 2023</xref>) (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>), with the species set to &#x201c;<italic>Homo sapiens</italic>&#x201d; and the protein interaction confidence threshold set to &#x2265;0.40 to filter out nodes lacking interaction. The screening results were exported and a drug-compound-target regulatory network was constructed in Cytoscape 3.8.0. In this network, drugs, compounds, and targets were represented by red diamonds, blue circles, and green triangles, respectively, with the edge weight reflecting the degree centrality of the nodes. Degree centrality analysis of the network was performed using the CytoNCA plugin to calculate the degree centrality values of the core compounds, which were then ranked to identify the core compounds.</p>
</sec>
<sec id="s2-1-4">
<title>2.1.4 Construction of the protein-protein interaction network and identification of core proteins</title>
<p>The drug and diabetes common targets were imported into the STRING platform (<ext-link ext-link-type="uri" xlink:href="https://cn.string-db.org/">https://cn.string-db.org/</ext-link>) to construct the Protein-Protein Interaction (PPI) Network (The network was constructed with &#x201c;<italic>Homo sapiens</italic>&#x201d; as the species, confidence set at 0.90, and isolated nodes were removed). The common target network data obtained from the STRING platform was then imported into Cytoscape 3.9.1, where the cytoHubba plugin was used to analyze five network topological parameters of the PPI network: Degree Centrality (DC), Betweenness Centrality (BC), Closeness Centrality (CC), Maximal Clique Centrality (MCC), and Maximum Neighborhood Component (MNC). The average value for each parameter was calculated, and data exceeding the average values were selected for Venn analysis, followed by the construction of the corresponding PPI network diagram. Subsequently, targets exceeding the average values of each parameter were then displayed and identified as the core targets of the &#x201c;Astragalus-Dangshen&#x201d; herbal pair in the treatment of T2DM.</p>
</sec>
<sec id="s2-1-5">
<title>2.1.5 Cluster analysis</title>
<p>In order to identify the core sub-clusters within the PPI network, this study employed the MCODE plugin in Cytoscape 3.9.1 to perform cluster analysis on the intersected target network. The filter conditions were set as follows: Degree Cutoff &#x3d; 2, K-core &#x3d; 2, and Max. Depth &#x3d; 100.</p>
</sec>
<sec id="s2-1-6">
<title>2.1.6 Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis</title>
<p>Finally, GO and KEGG pathway (<xref ref-type="bibr" rid="B14">Kanehisa et al., 2017</xref>; <xref ref-type="bibr" rid="B13">Kanehisa et al., 2023</xref>) enrichment analysis were performed by ShinyGO 0.82. All enrichment analyses were conducted in the &#x201c;<italic>Homo sapiens</italic>&#x201d; species, with results selected at P &#x3c; 0.01 to identify biological processes (BP), cellular components (CC), molecular functions (MF), and KEGG signaling pathways associated with glucose regulation, thereby further exploring the potential mechanisms of &#x201c;Huangqi-Dangshen&#x201d; medicinal pair in blood glucose regulation.</p>
</sec>
</sec>
<sec id="s2-2">
<title>2.2 Molecular docking</title>
<p>The diabetic-related receptor proteins identified in <xref ref-type="sec" rid="s2-1">Section 2.1</xref> were preprocessed using Discovery Studio 2019 win, which primarily involved repairing missing residues, optimizing protonation states, and removing crystallization water molecules to ensure the structural integrity of the receptor. Then, using the semi-flexible docking method in the CDOCKER module (<xref ref-type="bibr" rid="B32">Tessaro and Scapozza, 2020</xref>), the residues within a 10&#xa0;&#xc5; range of the eutectic ligand were defined as the active pocket, and the binding process between the ligand and receptor protein was simulated. In the end, according to the energy score and screening results, the best binding mode was selected as the initial conformation of the subsequent molecular dynamics simulation.</p>
</sec>
<sec id="s2-3">
<title>2.3 Molecular dynamics simulation</title>
<p>Based on the results from <xref ref-type="sec" rid="s2-2">Section 2.2</xref>, this study performed molecular dynamics simulations to investigate the binding of rhamnocitrin and folic acid with the target protein GSK3&#x3b2;. Molecular dynamics simulation can simulate the movement and interaction of molecules at the atomic level, and analyze the dynamic changes of proteins, ligands and the environment, so as to provide information on the behavior of molecular conformational change, binding stability and dynamics between protein and ligand. In this study, Schrodinger 2024 Linux program was used to construct a molecular dynamics simulation system. In the simulation system, the receptor-ligand complex was placed in a TIP3P water solvent model, with the box boundary set at least 12&#xa0;&#xc5; away from the complex to ensure adequate solvation of water molecules and avoid boundary effects. The ion concentration in the system was set to 0.154&#xa0;M, with Na<sup>&#x2b;</sup> and Cl<sup>&#x2212;</sup> used to neutralize the charge of the system in the simulation process. To enhance simulation accuracy, the OPLS3e force field (<xref ref-type="bibr" rid="B33">Tirado-Rives and Jorgensen, 2008</xref>) was employed in the system, which effectively describes non-bonded interactions and binding modes between molecules, particularly suited for the study of protein-ligand complexes (<xref ref-type="bibr" rid="B37">Wu et al., 2022</xref>; <xref ref-type="bibr" rid="B3">Collier et al., 2020</xref>).</p>
<p>In the initial energy optimization, the steepest descent method was adopted for 5,000 steps to minimize unreasonable contact and high-energy conformations, with a convergence threshold set at 10&#xa0;kJ/mol/nm to ensure effective adjustment of the force field parameters. Then the conjugate gradient method was applied for 2000 steps to optimize the thermodynamic state of the system in an effort to guarantee its stability (<xref ref-type="bibr" rid="B17">Levitt and Lifson, 1969</xref>; <xref ref-type="bibr" rid="B24">Powell, 1977</xref>; <xref ref-type="bibr" rid="B7">Fletcher, 2013</xref>).</p>
<p>When entering the equilibrium phase, the NVT ensemble simulation of 100&#xa0;ps with a time step of 2 fs was first performed, and the system was gradually heated to 300&#xa0;K so as to eliminate the influence of the initial structure and make sure thermodynamic equilibrium. This was followed by switching to the NPT ensemble for further equilibration at a constant pressure of 1&#xa0;bar, with a simulation time of 100&#xa0;ps to stabilize the density and pressure. The primary purpose of this stage was to allow the system to reach a stable thermodynamic state, preparing it for subsequent production simulations (<xref ref-type="bibr" rid="B44">Zhao et al., 2007</xref>; <xref ref-type="bibr" rid="B36">Wen et al., 2003</xref>).</p>
<p>The formal molecular dynamics simulations ran for 100&#xa0;ns, during which the temperature was maintained at 300&#xa0;K, the pressure at 1&#xa0;bar, with the time step of 2&#xa0;fs and trajectory sampling interval of 10&#xa0;ps. In order to ensure the stability and accuracy of the simulation, physical properties such as temperature, pressure and volume were regularly monitored during simulation process to ensure they remained within the expected range.</p>
</sec>
<sec id="s2-4">
<title>2.4 Alanine flexible scanning</title>
<p>On the basis of molecular dynamics simulation, in order to further analyze the interactions between ligands and key residues of diabetes-related target proteins, the Discovery Studio 2021 program was utilized in this study to carry out alanine flexible scanning. Alanine scanning replaces critical residues with alanine to identify residues that play a crucial role in ligand binding, and to assess their impact on the binding interface and affinity. The scanning targets are all amino acid residues within a 3&#xa0;&#xc5; radius of the ligand-binding interface.</p>
</sec>
<sec id="s2-5">
<title>2.5 Theoretical calculation of DFT</title>
<p>In this study, density functional theory (DFT) (<xref ref-type="bibr" rid="B43">Zhao et al., 2004</xref>; <xref ref-type="bibr" rid="B25">Qin et al., 2018</xref>) was used to evaluate the chemical activity of Astragalus-Codonopsis drugs on core components. Firstly, the geometric structures were optimized at the B3LYP/6-311G D3 (d, p) level (<xref ref-type="bibr" rid="B8">Harder et al., 2016</xref>)by the using of Gaussian 09w Linux program. After optimization, single-point energy calculations were performed under the same basis set, and energy distribution data for the Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) were extracted (<xref ref-type="bibr" rid="B40">Zhang and Musgrave, 2007</xref>). By analyzing the HOMO-LUMO gap and orbital spatial distribution, the electronic excitation properties of the core components and their electron transfer activity at the GSK3&#x3b2; protein binding interface were evaluated. In addition, the HOMO-LUMO orbital distribution and electron density plots were analyzed and visualized using Multiwfn_3.8 (<xref ref-type="bibr" rid="B20">Lu and Chen, 2012</xref>; <xref ref-type="bibr" rid="B19">Lu, 2024</xref>).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Analysis of the results of network pharmacology study of Astragalus-Codonopsis in the treatment of diabetes</title>
<sec id="s3-1-1">
<title>3.1.1 Intersection gene targets analysis</title>
<p>Based on the research methodology outlined in <xref ref-type="sec" rid="s2-1">Section 2.1</xref>, a total of 70 potential bioactive compounds and 300 associated drug targets from the Astragalus- Codonopsis pharmaceutical pair were identified. Subsequently, 4,681 disease-related targets associated with Type 2 Diabetes were obtained from disease databases, and through cross-analysis, 104 drug-disease target intersections were selected (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Additionally, a &#x201c;Traditional Chinese Medicine-Active Compounds-Target Network&#x201d; was successfully constructed by Cytoscape 3.9.1 (<xref ref-type="bibr" rid="B27">Shannon et al., 2003</xref>) (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Based on this, 95 nodes and 618 interaction relationships were obtained. Moreover, 12 key active compounds were further selected based on their degree values (<xref ref-type="table" rid="T1">Table 1</xref>) by CytoNCA plug-in of Cytoscape 3.9.1.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>
<bold>(A)</bold> Common targets for diseases and drugs. <bold>(B)</bold> Traditional Chinese Medicine-active ingredients-target genes.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g001.tif">
<alt-text content-type="machine-generated">Venn diagram and network graph illustrating Type 2 diabetes analysis. The Venn diagram on the left shows overlaps between HQ, DS, and Type 2 diabetes. The network graph on the right displays connections, with nodes HQ, DS, and diabetes-related elements connected via lines, demonstrating relationships and interactions.</alt-text>
</graphic>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Degree values of core drugs ingredients.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Compound</th>
<th align="center">Degree</th>
<th align="center">CAS</th>
<th align="center">Compound</th>
<th align="center">Degree</th>
<th align="center">CAS</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Rhamnocitrin</td>
<td align="center">79</td>
<td align="center">569&#x2013;92-6</td>
<td align="center">Mucronulatol</td>
<td align="center">25</td>
<td align="left">20,878&#x2013;98-2</td>
</tr>
<tr>
<td align="center">Folic acid</td>
<td align="center">56</td>
<td align="center">59&#x2013;30-3</td>
<td align="center">Tangshenoside III_qt</td>
<td align="center">22</td>
<td align="left">129,277&#x2013;39-0</td>
</tr>
<tr>
<td align="center">Isorhamnetin</td>
<td align="center">56</td>
<td align="center">480&#x2013;19-3</td>
<td align="center">7-O-Methylisomucronulatol</td>
<td align="center">21</td>
<td align="left">137,217&#x2013;83-5</td>
</tr>
<tr>
<td align="center">Glycitein</td>
<td align="center">37</td>
<td align="center">40,957&#x2013;83-3</td>
<td align="center">Tectorigenin</td>
<td align="center">21</td>
<td align="left">548&#x2013;77-6</td>
</tr>
<tr>
<td align="center">Calycosin</td>
<td align="center">28</td>
<td align="center">20,575&#x2013;57-9</td>
<td align="center">7-Methoxy-2-methyl isoflavone</td>
<td align="center">18</td>
<td align="left">19,725&#x2013;44-1</td>
</tr>
<tr>
<td align="center">Formononetin</td>
<td align="center">25</td>
<td align="center">485&#x2013;72-3</td>
<td align="center">1-(2,4-Dihydroxyphenyl)-3-</td>
<td rowspan="2" align="center">19</td>
<td rowspan="2" align="left">961&#x2013;29-5</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="center">(4-Hydroxyphenyl) prop-2-en-1-one</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-1-2">
<title>3.1.2 PPI network analysis of key targets of anti-T2DM</title>
<p>The five network topological parameters of the intersected target network were calculated using the &#x201c;cytoHubba&#x201d; plugin. PPI network diagrams associated with these five parameters were subsequently plotted (<xref ref-type="fig" rid="F2">Figure 2</xref>). Through Venn analysis, 17 core targets were identified, including GSK3B, TP53, PTGS2, INS, IL1B, among others (<xref ref-type="fig" rid="F3">Figure 3A</xref>; <xref ref-type="table" rid="T2">Table. 2</xref>). Finally, the core protein-protein interaction network of the &#x201c;Astragalus-Dangshen&#x201d; herbal pair in the treatment of T2DM was visualized (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The PPI network for 104 overlapping genes (The size and color of the nodes were positively correlated with the target&#x2019;s degree of association.).</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g002.tif">
<alt-text content-type="machine-generated">Five network diagrams titled Degree, MNC, Betweenness, MCC, and Closeness show interconnected nodes with various sizes and colors. Larger red nodes, such as GSK3B and TP53, indicate significant connections, while smaller yellow nodes form outer rings. Lines represent interactions among nodes, illustrating network centrality and importance metrics.</alt-text>
</graphic>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> The venn diagram for MCC, MNC, DC, CC and BC <bold>(B)</bold> 104 common targets PPI network. The highlighted targets originate from the key intersecting nodes determined by the preceding Venn diagram analysis <bold>(C)</bold> PPI network of the key genes; PPI network by the screening criteria of DC &#x2265; 26.29, BC &#x2265; 100.85, CC &#x2265; 0.534090909, MCC &#x2265; 88570.58, MNC &#x2265; 25.32.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g003.tif">
<alt-text content-type="machine-generated">Venn diagram (A) combines MCC Score, MNC Score, Degree, Betweenness, and Closeness, highlighting shared genes. Network diagrams (B, C) show gene interactions with various nodes and connections. Bar chart and number distribution illustrate list sizes and overlaps. Interaction key explains color-coded relationship types.</alt-text>
</graphic>
</fig>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Analysis of the network topological parameters of key targets.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">NO.</th>
<th align="center">Gene name</th>
<th align="center">Betweenness</th>
<th align="center">Closeness</th>
<th align="center">MNC score</th>
<th align="center">MCC score</th>
<th align="center">Degree</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">GSK3B</td>
<td align="center">1,075.30</td>
<td align="center">0.74</td>
<td align="center">71</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">104</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">PTGS2</td>
<td align="center">701.91</td>
<td align="center">0.71</td>
<td align="center">62</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">63</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">ESR1</td>
<td align="center">574.35</td>
<td align="center">0.69</td>
<td align="center">59</td>
<td align="center">1.04 &#xd7; 10<sup>16</sup>
</td>
<td align="center">61</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">TNF</td>
<td align="center">464.45</td>
<td align="center">0.66</td>
<td align="center">55</td>
<td align="center">5.33 &#xd7; 10<sup>12</sup>
</td>
<td align="center">56</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">IL6</td>
<td align="center">363.12</td>
<td align="center">0.68</td>
<td align="center">57</td>
<td align="center">2.65 &#xd7; 10<sup>11</sup>
</td>
<td align="center">57</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">IL1B</td>
<td align="center">349.15</td>
<td align="center">0.71</td>
<td align="center">63</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">64</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">TP53</td>
<td align="center">282.42</td>
<td align="center">0.67</td>
<td align="center">60</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">60</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">INS</td>
<td align="center">291.48</td>
<td align="center">0.65</td>
<td align="center">52</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">52</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">EGFR</td>
<td align="center">291.25</td>
<td align="center">0.67</td>
<td align="center">58</td>
<td align="center">1.04 &#xd7; 10<sup>16</sup>
</td>
<td align="center">59</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">HIF1A</td>
<td align="center">286.13</td>
<td align="center">0.63</td>
<td align="center">52</td>
<td align="center">1.05 &#xd7; 10<sup>16</sup>
</td>
<td align="center">53</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">PPARG</td>
<td align="center">217.35</td>
<td align="center">0.66</td>
<td align="center">57</td>
<td align="center">8.37 &#xd7; 10<sup>15</sup>
</td>
<td align="center">57</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">MAPK1</td>
<td align="center">249.61</td>
<td align="center">0.58</td>
<td align="center">39</td>
<td align="center">8.92 &#xd7; 10<sup>13</sup>
</td>
<td align="center">39</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">RELA</td>
<td align="center">148.25</td>
<td align="center">0.61</td>
<td align="center">45</td>
<td align="center">4.43 &#xd7; 10<sup>15</sup>
</td>
<td align="center">45</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">ESR2</td>
<td align="center">114.67</td>
<td align="center">0.57</td>
<td align="center">34</td>
<td align="center">5.69 &#xd7; 10<sup>12</sup>
</td>
<td align="center">35</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">BCL2</td>
<td align="center">148.47</td>
<td align="center">0.65</td>
<td align="center">54</td>
<td align="center">5.31 &#xd7; 10<sup>8</sup>
</td>
<td align="center">55</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">IL10</td>
<td align="center">132.13</td>
<td align="center">0.63</td>
<td align="center">49</td>
<td align="center">1.04 &#xd7; 10<sup>16</sup>
</td>
<td align="center">50</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">PPARGC1A</td>
<td align="center">192.80</td>
<td align="center">0.59</td>
<td align="center">41</td>
<td align="center">8.37 &#xd7; 10<sup>15</sup>
</td>
<td align="center">41</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-1-3">
<title>3.1.3 Cluster analysis</title>
<p>Cluster analysis revealed that the PPI network could be partitioned into six distinct modules (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;F</xref>; <xref ref-type="table" rid="T3">Table 3</xref>). Module 1 emerged as the central hub of the PPI network, exhibiting a significantly higher cluster score (score &#x3d; 34.15) compared to other modules. Notably, all core targets identified in Method 1.1.2 were localized within Module 1, further underscoring the pivotal role of these targets in the therapeutic mechanism of the Astragalus-Codonopsis herb pair for T2DM management.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Cluster analysis of the overlapping protein-protein interaction (PPI) network comprising 104 nodes <bold>(A)</bold> Cluster 1 contains 38 nodes connected by 620 edges (cluster score &#x3d; 32.21) <bold>(B)</bold> Cluster 2 consists of 10 nodes with 29 edges (score &#x3d; 6.44) <bold>(C)</bold> Cluster 3 includes 7 nodes and 19 edges (score &#x3d; 6.33) <bold>(D)</bold> Cluster 4 comprises 5 nodes and 8 edges (score &#x3d; 4.00) <bold>(E,F)</bold> Cluster 5 and 6 each contain 3 nodes connected by 3 edges (score &#x3d; 3.00) The size and color of the nodes were positively correlated with the target&#x2019;s degree of association.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g004.tif">
<alt-text content-type="machine-generated">Six network diagrams labeled A to F, displaying interconnected nodes with varying sizes and colors. A shows a large interconnected network with a focus on IL1B, CASP3. B highlights IL6, INS, TNF interactions. C centers on ADRA2E connections. D focuses on GABRA1 with links to CHRM nodes. E shows a triangle connecting NCOA2, NCOA1, and CTSD. F depicts connections among GOT2, LPL, and ACACA.</alt-text>
</graphic>
</fig>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Cluster information of the common targets for diseases and drugs.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Cluster</th>
<th align="center">Score</th>
<th align="center">Nodes</th>
<th align="center">Edges</th>
<th align="center">Node IDs</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">32.21</td>
<td align="center">38</td>
<td align="center">620</td>
<td align="center">IL10, EP300, PPARG, MMP1, IL4, NFE2L2, TP53, IGF1R, BCL2L1, EGFR, AR, HIF1A, CXCL8, NFKBIA, IL1B, PLAU, ESR1, IFNG, MAPK14, HMOX1, MMP9, CASP3, IL2, SERPINE1, GSK3B, AKT1, CDKN1A, ESR2, MMP2, ERBB2, PTGS2, CASP9, RELA, NOS2, MAPK1, ICAM1, BCL2, KDR</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">6.44</td>
<td align="center">10</td>
<td align="center">29</td>
<td align="center">SLC2A4, TNF, XDH, PPARA, IL6, INS, PGR, MET, CD40LG, PPARGC1A</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">6.33</td>
<td align="center">7</td>
<td align="center">19</td>
<td align="center">ADRA2C, SLC6A2, ADRA2B, ADRA1A, ADRA2A, ADRA1D, ADRA1B</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">4.00</td>
<td align="center">5</td>
<td align="center">8</td>
<td align="center">GABRA1, SLC6A4, CHRM1, CHRM3, CHRM2</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">3.00</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">CTSD, NCOA2, NCOA1</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">3.00</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">GOT2, ACACA, LPL</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-1-4">
<title>3.1.4 Functional enrichment analysis of intersection target of Astragalus-Codonopsis pairs and T2DM</title>
<p>The functional enrichment analysis was performed on the 104 potential target genes identified by the use of DAVID 6.8 database (<xref ref-type="bibr" rid="B29">Sherman et al., 2022</xref>; <xref ref-type="bibr" rid="B10">Huang et al., 2009</xref>) which included GO enrichment analysis and KEGG pathway analysis. The GO analysis primarily includes three components: stands for Biological Process (BP), stands for Cellular Component (CC), and stands for Molecular Function (MF). The top 15 pathways with the smallest p-values from the gene enrichment analysis (<xref ref-type="fig" rid="F5">Figure 5A</xref>) and the top 30 KEGG pathways with the smallest p-values (<xref ref-type="fig" rid="F5">Figure 5B</xref>) were visualized. The results indicated that the IRSP is a key pathway through which the Astragalus-Codonopsis pharmaceutical pair regulates Type 2 Diabetes Mellitus (T2DM). Based on the above research content, we propose that the main bioactive compounds of the Astragalus- Codonopsis pharmaceutical pair regulate blood glucose levels by binding to GSK3&#x3b2; protein and modulating the expression of the insulin receptor signaling pathway.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> GO enrichment analysis <bold>(B)</bold> KEGG pathway enrichment analysis ingredients-target genes.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g005.tif">
<alt-text content-type="machine-generated">Bar graphs showing enriched pathways. Graph A displays biological processes (BP), cellular components (CC), and molecular functions (MF) with corresponding counts. Graph B highlights specific pathways like insulin receptor signaling and apoptosis, with bars colored by p-value according to the legend.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s3-2">
<title>3.2 Results of molecular docking between Astragalus-Codonopsis pair and core target GSK3&#x3b2;</title>
<p>In this study, the binding pattern and affinity of 13 core components from Astragalus and Codonopsis Radix with their core targets were evaluated by molecular docking technology. Ultimately, two ligand-protein complexes with stronger binding effects were selected and assessed. As shown in <xref ref-type="fig" rid="F6">Figure 6</xref>, among the 13 core compounds, compound Rh (rhamnocitrin) exhibited relatively stable binding with the GSK3&#x3b2; protein, especially the formation of hydrogen bonds with residues Lys205 and Asn213, and interacting with other amino acid residues through van der Waals forces, resulting in a docking score of 119.1087. This indicates that it has strong binding affinity. In contrast, the binding of compound Fa (folic acid) with protein GSK3&#x3b2; involved more amino acid residues, forming multiple hydrogen bonds between Ser66, Gly63, Phe67, Gly65, and Asp133, with a docking score of 130.2159, indicating higher binding stability.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Molecular docking of target protein GSK3&#x03B2; and two screened key ingredients. Docking diagram of rhamnocitrin and folic with protein GSK3&#x03B2;.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g006.tif">
<alt-text content-type="machine-generated">Diagram showing two protein-ligand interactions. Panel A: Chemical structure with interacting amino acids, surface structure, and close-up of ligand binding with distances labeled. Panel B: Similar layout with a different chemical structure and amino acids. Both panels highlight specific interactions within the protein complex structure.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Alanine flexible scanning</title>
<p>The alanine scanning results indicate that the binding energies of mutations at residues Arg180, Lys165 and Val214 on chain A, and Lys292 and Phe293 on chain B, were all greater than 0.5 after alanine substitution for the Rh-GSK3&#x03B2; complex (<xref ref-type="table" rid="T4">Table 4</xref>). This suggests that the binding interaction between GSK3&#x3b2; protein and rhamnocitrin was weakened, leading to a disruption in the stability of the complex after the mutation. Similarly, in the Fa-GSK3&#x3b2; complex (<xref ref-type="table" rid="T5">Table 5</xref>), when the residues Gly65, Val70, Lys85, and Leu132 were all replaced with alanine on protein chain A, the binding energies increased to varying degrees, which meant that the stability of the complex was more destroyed. These results suggest that the aforementioned amino acids play a magnificent role in the binding process between folate and the key protein GSK3&#x3b2;, which is consistent with the previous molecular docking findings.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Virtual alanine scanning mutagenesis of the rhamnocitrin-protein GSK3&#x3b2;.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">GSK3&#x3b2;-Rh-mutation</th>
<th align="center">Mutation energy<sup>kcal/mol</sup>
</th>
<th align="center">Effect of mutation</th>
<th align="center">VDW term</th>
<th align="center">Electrostatic term</th>
<th align="center">Entropy</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">A: Phe67 &#x3e; ALA</td>
<td align="left">0.31</td>
<td align="left">Neutral</td>
<td align="left">0.73</td>
<td align="left">&#x2212;0.07</td>
<td align="left">&#x2212;0.02</td>
</tr>
<tr>
<td align="left">A: Arg180 &#x3e; ALA</td>
<td align="left">1.57</td>
<td align="left">Destabilizing</td>
<td align="left">2.00</td>
<td align="left">0.79</td>
<td align="left">0.22</td>
</tr>
<tr>
<td align="left">A: Lys205 &#x3e; ALA</td>
<td align="left">1.60</td>
<td align="left">Destabilizing</td>
<td align="left">2.04</td>
<td align="left">0.69</td>
<td align="left">0.29</td>
</tr>
<tr>
<td align="left">A: Pro212 &#x3e; ALA</td>
<td align="left">0.10</td>
<td align="left">Neutral</td>
<td align="left">0.16</td>
<td align="left">0.04</td>
<td align="left">0.00</td>
</tr>
<tr>
<td align="left">A: Asn213 &#x3e; ALA</td>
<td align="left">0.19</td>
<td align="left">Neutral</td>
<td align="left">0.47</td>
<td align="left">&#x2212;0.11</td>
<td align="left">0.01</td>
</tr>
<tr>
<td align="left">A: Val214 &#x3e; ALA</td>
<td align="left">0.55</td>
<td align="left">Destabilizing</td>
<td align="left">1.28</td>
<td align="left">&#x2212;0.11</td>
<td align="left">&#x2212;0.04</td>
</tr>
<tr>
<td align="left">A: Ile217 &#x3e; ALA</td>
<td align="left">0.37</td>
<td align="left">Neutral</td>
<td align="left">0.66</td>
<td align="left">0.04</td>
<td align="left">0.02</td>
</tr>
<tr>
<td align="left">B: Val263 &#x3e; ALA</td>
<td align="left">0.37</td>
<td align="left">Neutral</td>
<td align="left">0.76</td>
<td align="left">&#x2212;0.05</td>
<td align="left">0.02</td>
</tr>
<tr>
<td align="left">B: Lys292 &#x3e; ALA</td>
<td align="left">0.58</td>
<td align="left">Destabilizing</td>
<td align="left">2.67</td>
<td align="left">&#x2212;0.62</td>
<td align="left">&#x2212;0.55</td>
</tr>
<tr>
<td align="left">B: Phe293 &#x3e; ALA</td>
<td align="left">1.18</td>
<td align="left">Destabilizing</td>
<td align="left">2.40</td>
<td align="left">&#x2212;0.1</td>
<td align="left">0.04</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Virtual alanine scanning mutagenesis of the folic acid-protein GSK3&#x3b2;.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">GSK3&#x3b2;-Fa mutation</th>
<th align="center">Mutation energy<sup>kcal/mol</sup>
</th>
<th align="center">Effect of mutation</th>
<th align="center">VDW term</th>
<th align="center">Electrostatic term</th>
<th align="center">Entropy</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">A: Gly65 &#x3e; ALA</td>
<td align="left">3.05</td>
<td align="left">Destabilizing</td>
<td align="left">5.34</td>
<td align="left">0.76</td>
<td align="left">0.00</td>
</tr>
<tr>
<td align="left">A: Ser66 &#x3e; ALA</td>
<td align="left">&#x2212;0.17</td>
<td align="left">Neutral</td>
<td align="left">&#x2212;0.24</td>
<td align="left">&#x2212;0.12</td>
<td align="left">0.01</td>
</tr>
<tr>
<td align="left">A: Phe67 &#x3e; ALA</td>
<td align="left">0.18</td>
<td align="left">Neutral</td>
<td align="left">0.62</td>
<td align="left">&#x2212;0.18</td>
<td align="left">&#x2212;0.05</td>
</tr>
<tr>
<td align="left">A: Gly68 &#x3e; ALA</td>
<td align="left">&#x2212;0.27</td>
<td align="left">Neutral</td>
<td align="left">&#x2212;0.57</td>
<td align="left">0.07</td>
<td align="left">&#x2212;0.02</td>
</tr>
<tr>
<td align="left">A: Val70 &#x3e; ALA</td>
<td align="left">0.68</td>
<td align="left">Destabilizing</td>
<td align="left">1.54</td>
<td align="left">&#x2212;0.24</td>
<td align="left">0.04</td>
</tr>
<tr>
<td align="left">A: Ala83 &#x3e; ALA</td>
<td align="left">0.05</td>
<td align="left">Neutral</td>
<td align="left">0.12</td>
<td align="left">&#x2212;0.02</td>
<td align="left">0.00</td>
</tr>
<tr>
<td align="left">A: Lys85 &#x3e; ALA</td>
<td align="left">1.69</td>
<td align="left">Destabilizing</td>
<td align="left">2.03</td>
<td align="left">1.11</td>
<td align="left">0.15</td>
</tr>
<tr>
<td align="left">A: Val110 &#x3e; ALA</td>
<td align="left">0.22</td>
<td align="left">Neutral</td>
<td align="left">0.42</td>
<td align="left">0.02</td>
<td align="left">0.00</td>
</tr>
<tr>
<td align="left">A: Leu132 &#x3e; ALA</td>
<td align="left">0.63</td>
<td align="left">Destabilizing</td>
<td align="left">1.18</td>
<td align="left">&#x2212;0.04</td>
<td align="left">0.08</td>
</tr>
<tr>
<td align="left">A:Asp133 &#x3e; ALA</td>
<td align="left">&#x2212;0.24</td>
<td align="left">Neutral</td>
<td align="left">0.05</td>
<td align="left">&#x2212;0.52</td>
<td align="left">0.00</td>
</tr>
<tr>
<td align="left">A: Tyr134 &#x3e; ALA</td>
<td align="left">0.41</td>
<td align="left">Neutral</td>
<td align="left">0.64</td>
<td align="left">0.00</td>
<td align="left">0.11</td>
</tr>
<tr>
<td align="left">A: Val135 &#x3e; ALA</td>
<td align="left">0.03</td>
<td align="left">Neutral</td>
<td align="left">0.11</td>
<td align="left">&#x2212;0.07</td>
<td align="left">0.01</td>
</tr>
<tr>
<td align="left">A: Leu188 &#x3e; ALA</td>
<td align="left">0.15</td>
<td align="left">Neutral</td>
<td align="left">0.33</td>
<td align="left">&#x2212;0.05</td>
<td align="left">0.01</td>
</tr>
<tr>
<td align="left">A: Cys199 &#x3e; ALA</td>
<td align="left">0.02</td>
<td align="left">Neutral</td>
<td align="left">0.04</td>
<td align="left">&#x2212;0.03</td>
<td align="left">0.02</td>
</tr>
<tr>
<td align="left">A: Asp200 &#x3e; ALA</td>
<td align="left">&#x2212;0.20</td>
<td align="left">Neutral</td>
<td align="left">2.08</td>
<td align="left">&#x2212;2.41</td>
<td align="left">&#x2212;0.04</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-4">
<title>3.4 Molecular dynamics simulation results</title>
<p>Based on the results of molecular docking, we simulated the molecular dynamics of two groups of receptor-ligand complexes (Rh-GSK3&#x3b2;, Fa-GSK3&#x3b2;) over a period of 100&#xa0;ns The complexes formed by rhamnocitrin (Rh) and folic acid (Fa) with GSK3&#x3b2; exhibited structural stability, as demonstrated by molecular dynamics simulations. <xref ref-type="fig" rid="F7">Figures 7A</xref>,<xref ref-type="fig" rid="F7">B</xref> show the changes of RMSD (Root Mean Square Deviation) of the complex formed by the combination of active ingredient Rh and Fa with protein GSK3&#x3b2; in a vivo environment, respectively. In the FA-GSK3&#x3b2; complex, the binding of compound Fa with protein GSK3&#x3b2; shows a significant conformational reversal at the 20th ns, after which the RMSD fluctuation maintained around 3.6&#xa0;&#xc5; steadily, exhibiting good uniformity, and the conformational changes of receptor and ligand were synchronized. The RMSD fluctuation of complex Rh-GSK3&#x3b2; began to rise around the 30th ns, and the fluctuation became stable at the 40th ns. Finally, the conformation changes of protein stabilized around 4&#xa0;&#xc5;, while the conformation change of ligand stabilized around 3.2&#xa0;&#xc5;. Subsequently, we analyzed the changes in RMSF (Root Mean Square Fluctuation) of the two groups of complex systems (<xref ref-type="fig" rid="F7">Figures 7C,D</xref>), the value of which represents the flexibility of the corresponding amino acid residues. The results show that amino acid residues in contact with the core components in contact with the core components exhibit minimal fluctuation, suggesting lower flexibility and higher rigidity, that is, the fluctuation of the residues of the receptor remain relatively stable, and the binding of the core components Rh and Fa to the target protein GSK3&#x3b2; maintain stable, reducing the possibility of deviation due to large fluctuations.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The variation profiles of RMSD and RMSF for the Rhamnocitrin- GSK3&#x3b2; complex and Folic Acid- GSK3&#x3b2; complex. RMSD of the Rhamnocitrin-Protein GSK3&#x3b2; <bold>(A)</bold> and Folic Acid-Protein GSK3&#x3b2; <bold>(B)</bold>; RMSF of the Rhamnocitrin-Protein GSK3&#x3b2; <bold>(C)</bold> and Folic Acid-Protein GSK3&#x3b2; <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g007.tif">
<alt-text content-type="machine-generated">Four graphs labeled A, B, C, and D display Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) data. Graphs A and B show protein and ligand RMSD over time with different atom types. Graphs C and D depict RMSF and B factor across residue index. Each graph has a legend differentiating C&#x3B1;, backbone, heavy atoms, ligand fit protein, and ligand fit ligand. Graphs C and D also include B factors.</alt-text>
</graphic>
</fig>
<p>In order to further investigate the physical and chemical pathways of selected ligand compounds binding to the receptor active pockets bind, the interaction analysis of the ligand-receptor binding interface was conducted (<xref ref-type="fig" rid="F8">Figures 8A,B</xref>). In the Rh-GSK3&#x3b2; system, the hydrogen bond interaction between the compound Rh and residues of Asn95 and Gln99 is formed, with the duration of this interaction exceeding 100% and 50%, respectively. In addition, the ligand Rh exhibits hydrophobic interactions with residues Val214, Tyr216, Ser261, Val263 and Asn285. In FA-GSK3&#x3b2; system, ligand Fa forms continuous hydrogen bonds with Ile62, Ser66 and Val135 residues, as well as with Asn64, Gln185 and Asp200 residues through water bridges. The hydrogen bond occupancy timeline diagram of the complex also confirmed this point (<xref ref-type="fig" rid="F8">Figures 8C,D</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>The ligand-receptor binding interface interaction analysis diagram of Rhamnocitrin-Protein GSK3&#x3b2; <bold>(A)</bold> and Folic Acid-Protein GSK3&#x3b2; <bold>(B)</bold>; the hydrogen bond occupancy timeline plot of Rhamnocitrin-Protein GSK3&#x3b2; <bold>(C)</bold> and Folic Acid-Protein GSK3&#x3b2; <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g008.tif">
<alt-text content-type="machine-generated">Charts A and B show interaction fractions for different residues, categorized by H-bonds, hydrophobic, ionic, and water bridges. Charts C and D are time-resolved interaction maps for different residues, with intensity variations depicted by color gradients over a timescale from 0 to 100 nanoseconds. Each chart provides detailed insights into molecular interaction dynamics.</alt-text>
</graphic>
</fig>
<p>Next, we specifically focused on investigating the impact of the ligands on the interactions within the complex systems (<xref ref-type="fig" rid="F9">Figure 9</xref>). The results indicate that the carbonyl, hydroxyl, and oxygen ions of the Rh ligand contribute most of the interaction of the complex interface. For example, the carbonyl group interacts with Arg180 residue of the A chain by dispersion-induced interaction in 25% of the total simulation time, while the hydroxyl group forms a water-bridge interaction with the Asp264 residue of chain B, with the interaction duration accounting for 28%. In the FA-GSK3&#x3b2; system, the N and O atoms of the ligand Fa play a crucial role in the binding process of the interface, forming persistent chemical interactions with several amino acid residues (such as water-bridge and salt-bridge interactions).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>The schematic of detailed ligand atom interactions with protein residues. Interaction diagram of Rhamnocitrin- GSK3&#x3b2; <bold>(A)</bold> and Folic Acid- GSK3&#x3b2; <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g009.tif">
<alt-text content-type="machine-generated">Complex molecular interaction diagrams labeled A and B show various chemical structures with interactions such as hydrogen bonds, pi-cation, salt bridges, and pi-pi stacking. The diagram uses colored circles to represent different properties: charged (negative), charged (positive), polar, hydrophobic, and water, with percentage values indicating interaction strength. Water molecules and exposure are also shown.</alt-text>
</graphic>
</fig>
<p>Finally, the torsion angle distribution histogram was used to quantitatively analyze the conformational changes of the ligands (<xref ref-type="fig" rid="F10">Figure 10</xref>). The study revealed that the C2-C1-O1-C3 dihedral angle of the Rh ligand exhibits a bimodal distribution (peaks at &#xb1; 45&#xb0;), indicating that the ligand is embedded in small cavities within the receptor pocket, demonstrating significant stability. In the Fa-GSK3&#x3b2; system, the rotation of the C-C bonds at positions 9 and 12 of the Fa ligand is significantly inhibited, suggesting that these portions are inserted into the binding pocket of the GSK3&#x3b2; protein, preventing bond rotation and indicating a stable binding interaction with the protein.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>The ligand torsion profile of ligand-protein. The diagram of Rhamnocitrin- GSK3&#x3b2; <bold>(A)</bold> and Folic Acid- GSK3&#x3b2; <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g010.tif">
<alt-text content-type="machine-generated">Chemical structures and data visualization diagrams. Panel A shows a chemical structure with a benzene ring and various functional groups. Panel B depicts a different chemical structure with a complex molecule and multiple functional groups. Panel C includes circular and histogram plots with color-coded segments and distribution graphs. Panel D displays additional circular and histogram plots with various colors and data arrangements.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-5">
<title>3.5 The DFT theoretical calculations of Rh and Fa</title>
<p>The computational results (<xref ref-type="fig" rid="F11">Figure 11</xref>) show that the low HOMO-LUMO gaps (0.12&#xa0;eV for Rh, 0.21&#xa0;eV for Fa) suggest enhanced electron transfer activity, facilitating interactions with polar residues of GSK3&#x3b2;. The HOMO orbital of rhamnolitrin is predominantly localized on the double bond and hydroxyl group of the pyran ring, as well as the phenolic hydroxyl group of the attached benzene ring, while the LUMO orbital is distributed over the carbon-oxygen double bond of the pyran ring and the carbon-carbon single bond connecting to the benzene ring. This configuration suggests that the electron tends to transfer from the benzene ring to the pyran ring. Furthermore, its low energy gap facilitates electron transfer within the GSK3&#x3b2; protein&#x2019;s binding pocket, leading to the rearrangement of electron clouds in the polar amino acid residues, thereby strengthening the hydrogen bonding and enhancing the binding stability between rhamnetin and GSK3&#x3b2;. In addition, the delocalized &#x3c0;-electron system in the structure of rhamnolitrin can engage in &#x3c0;-&#x3c0; stacking or cation-&#x3c0; interactions with aromatic residues (such as Phe and Tyr), synergistically enhancing the binding stability. The HOMO orbital of the folic acid molecule is primarily distributed on the amine group and the phenyl ring of the para-aminobenzoic acid, while the LUMO orbital is concentrated on the adjacent pteridine structure. What&#x2019;s more, the low energy gap also enables electronic transfer potential. It is similar to the results observed for rhamnetin. Both molecules enhance their binding stability to the GSK3&#x3b2; protein through electronic transfer and &#x3c0;-&#x3c0; stacking effects.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>The HOMO-LUMO energy levels of rhamnocitrin <bold>(A)</bold> and folic acid <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g011.tif">
<alt-text content-type="machine-generated">Molecular structures labeled A and B show visualizations of LUMO and HOMO with energy levels. A has LUMO at -0.07 eV, HOMO at -0.19 eV, and &#x394;E of 0.12 eV. B has LUMO at -0.048 eV, HOMO at -0.26 eV, and &#x394;E of 0.212 eV.</alt-text>
</graphic>
</fig>
<p>In addition, the electron density map in <xref ref-type="fig" rid="F12">Figure 12</xref> further validates the binging mechanism of rhamnolitrin with target protein GSK3&#x3b2;. The electron density of folic acid is primarily concentrated on the pteridine structure and the carbonyl group of the amide bond, which may serve as potential binding sites for stable interaction with the target protein. The electron density distribution of rhamnolitrin is uniform, suggesting that its binding to GSK3&#x3b2; primarily relies on the delocalized &#x3c0;-electrons and the &#x3c0;-&#x3c0; accumulation with amino acid residues.</p>
<fig id="F12" position="float">
<label>FIGURE 12</label>
<caption>
<p>The electron density map and its 3D projection of rhamnocitrin <bold>(A)</bold> and folic acid <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g012.tif">
<alt-text content-type="machine-generated">3D topographic and 2D heat maps labeled A and B. A shows dense peaks and closely packed red hotspots with a color gradient legend. B depicts fewer peaks and dispersed red hotspots with a similar gradient legend. Both maps include axes with units in Bohr.</alt-text>
</graphic>
</fig>
<p>Through electrostatic potential analysis (<xref ref-type="fig" rid="F13">Figure 13</xref>), it was found that the electron density of rhamnolitrin is primarily concentrated on the carbonyl oxygen, hydroxyl and phenolic hydroxyl groups of the pyrene ring, which facilitates stable binding to the protein binding pocket through hydrogen bonding. The electron density of folic acid is concentrated on the nitrogen atom of the pyrazine ring in the pteridine structure and the carbonyl group of the benzamide. The results of the electrostatic potential analysis are consistent with the aforementioned computational findings, indicating that rhamnolitrin and folic acid achieve stable binding to the GSK3&#x3b2; protein binding pocket through hydrogen bonding and &#x3c0;-&#x3c0; stacking interactions at their active sites.</p>
<fig id="F13" position="float">
<label>FIGURE 13</label>
<caption>
<p>The electrostatic potential map pf Rhamnocitrin and Folic Acid (&#x3bc; represents the calculated dipole moment) (B).</p>
</caption>
<graphic xlink:href="fbioe-13-1618575-g013.tif">
<alt-text content-type="machine-generated">Molecular models of rhamnocitrin and folic acid are shown with colored electron density surfaces. Rhamnocitrin is on the left with a dipole moment of 9.167181, and folic acid on the right with a dipole moment of 3.253401. A color scale indicates electron density from red to blue.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s4">
<title>4 Discussion and conclusion</title>
<sec id="s4-1">
<title>4.1 Discussion</title>
<p>This study systematically elucidates the mechanism by which the &#x201c;Astragalus-Codonopsis&#x201d; herbal pair regulates GSK3&#x3b2;-mediated insulin signaling through multi-component synergy by the use of multi-level computational biology validation. The network pharmacology revealed that GSK3&#x3b2; is at the core of PPI network, which is highly consistent with the clinical studies linking GSK3&#x3b2; overexpression to insulin resistance. Molecular docking showed that rhamnolitrin and folic acid can bind stably to the binding pocket of GSK3&#x3b2; protein through various interactions such as hydrogen bonds. Alanine virtual scanning further validated the key amino acid residues of protein GSK3&#x3b2; that can bind with these core active ingredients.</p>
<p>The subsequent kinetic simulation revealed the dynamic interaction patterns of rhamnolitrin and folic acid with GSK3&#x3b2; protein in physiological environment. The RMSF and RMSD plots displayed the conformational changes of the complex formed between the compounds and GSK3&#x3b2; protein after the simulation started, with the receptor-ligand complex maintaining stability at the end of the simulation. Furthermore, the hydrogen bonding time diagram and key residue interaction analysis both elucidated the primary chemical interactions between two core components and the GSK3&#x3b2; protein binding pocket. The subsequent torsion distribution histogram visually demonstrated that rhamnolitrin and folic acid were stably inserted into the active cavity of the protein GSK3&#x3b2;, forming a stable &#x201c;lock-key chelation structure&#x201d;. Finally, the DFT theoretical calculation analyzed the quantum mechanical properties of rhamnolitrin and folic acid, further clarifying the binding mechanism: the phenolic hydroxyl group and carbonyl oxygen in the structure of rhamnolitrin serve as binding sites, potentially forming hydrogen bonds with the polar amino acid residues of the GSK3&#x3b2; protein. Meanwhile, the delocalized &#x3c0; electrons will also generate &#x3c0;-&#x3c0; accumulation to further stabilize the binding process. The folic acid achieves stable binding with the GSK3&#x3b2; protein through the pteridine part of its structure and the carbonyl oxygen of its amide bond. This may be the key mechanism by which the &#x201c;Astragalus- Codonopsis&#x201d; herbal pair reduces (QIAN, X, et al., 2019) GSK3&#x3b2; kinase activity and regulates the insulin receptor signaling pathway, thereby exerting its hypoglycemic effect.</p>
<p>This research has carried out methodological innovation and technical integration based on similar studies in the existing literature. Compared with the conventional research paradigm that combines network pharmacology with molecular docking, this project has constructed a multi-dimensional research system: By integrating technical means such as network pharmacology prediction, molecular docking verification, dynamic analysis of molecular dynamics simulation, key site identification of alanine scanning mutation technology, and DFT theoretical calculation, the multi-target action network and molecular mechanism of drug synergistic therapy for type 2 diabetes mellitus (T2DM) were systematically revealed. This multi-dimensional research strategy not only provides a theoretical basis for clinical transformation but also points out multiple potential targets for the development of new anti-diabetic drugs.</p>
</sec>
<sec id="s4-2">
<title>4.2 Conclusions</title>
<p>In this study, the molecular mechanism model of &#x201c;Astragalus-Codonopsis&#x201d; on the treatment of type 2 diabetes was established: rhamnolitrin and folic acid can bind to GSK3&#x3b2; protein through hydrogen bonding, van der Waals force and hydrophobic interaction, and regulate the insulin receptor signaling pathway to play a pharmacological role in its hypoglycemic effect. The results of this study not only provide a new method for the modernization of TCM compounds, but also lay a theoretical foundation for the development of multi-target hypoglycemic preparations based on natural products.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec sec-type="author-contributions" id="s6">
<title>Author contributions</title>
<p>JY: Writing &#x2013; original draft, Data curation. ML: Supervision, Writing &#x2013; original draft. ZZ: Investigation, Writing &#x2013; original draft. FH: Writing &#x2013; review and editing, Validation. YM: Writing &#x2013; review and editing, Formal Analysis. JH: Writing &#x2013; review and editing, Validation. QZ: Writing &#x2013; review and editing, Project administration. HY: Conceptualization, Writing &#x2013; review and editing. XL: Writing &#x2013; review and editing, Funding acquisition.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This work was financially supported by Ningxia Natural Science Foundation (No. 2023AAC03186 and 2024AAC03291).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s9">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2025.1618575/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2025.1618575/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantley</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>The phosphoinositide 3-kinase pathway</article-title>. <source>Science</source> <volume>296</volume> (<issue>5573</issue>), <fpage>1655</fpage>&#x2013;<lpage>1657</lpage>. <pub-id pub-id-type="doi">10.1126/science.296.5573.1655</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dworkin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The redox-sensitive GSK3&#x3b2; is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease</article-title>. <source>Redox Biol.</source> <volume>72</volume>, <fpage>103127</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2024.103127</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Piggot</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Molecular dynamics simulation of proteins</article-title>. <source>Methods Mol. Biol.</source> <volume>2073</volume>, <fpage>311</fpage>&#x2013;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-9869-2_17</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules</article-title>. <source>Acids Res.</source> <volume>47</volume> (<issue>W1</issue>), <fpage>W357</fpage>&#x2013;<lpage>W364</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz382</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupuy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Helbert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>DiceDesign and DiceEval: two R packages for design and analysis of computer experiments</article-title>. <source>J. Stat. Softw.</source> <volume>65</volume> (<issue>11</issue>), <fpage>1</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v065.i11</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Khodary</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Dabees</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Werida</surname>
<given-names>R. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Folic acid effect on homocysteine, sortilin levels and glycemic control in type 2 diabetes mellitus patients</article-title>. <source>Nutr. Diabetes</source> <volume>12</volume> (<issue>1</issue>), <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1038/s41387-022-00210-6</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filipe</surname>
<given-names>H. A. L.</given-names>
</name>
<name>
<surname>Loura</surname>
<given-names>L. M. S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Molecular dynamics simulations: advances and applications</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>7</issue>), <fpage>2105</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27072105</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <source>Practical methods of optimization</source>. <publisher-name>John Wiley and Sons</publisher-name>.</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harder</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Damm</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Maple</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reboul</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>J. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>OPLS3: a force field providing broad coverage of drug-like small molecules and proteins</article-title>. <source>J. Chem. Theory Comput.</source> <volume>12</volume> (<issue>1</issue>), <fpage>281</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00864</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>K. F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gui</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y. H.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The efficacy and safety of Astragalus as an adjuvant treatment for type 2 diabetes mellitus: a systematic review and meta-analysis</article-title>. <source>J. Integr. Complement. Med.</source> <volume>30</volume> (<issue>1</issue>), <fpage>11</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1089/jicm.2022.0767</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Lempicki</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources</article-title>. <source>Nat. Protoc.</source> <volume>4</volume> (<issue>1</issue>), <fpage>44</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>W. Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Screening for fractions of Oxytropis falcata Bunge with antibacterial activity</article-title>. <source>Nat. Prod. Res.</source> <volume>23</volume> (<issue>10</issue>), <fpage>953</fpage>&#x2013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1080/14786410902906934</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>W. Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S. X.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Antioxidant activities of extracts and flavonoid compounds from oxytropis falcate Bunge</article-title>. <source>Nat. Prod. Res.</source> <volume>22</volume> (<issue>18</issue>), <fpage>1650</fpage>&#x2013;<lpage>1656</lpage>. <pub-id pub-id-type="doi">10.1080/14786410701875686</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Furumichi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishiguro-Watanabe</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>KEGG for taxonomy-based analysis of pathways and genomes</article-title>. <source>Nucleic Acids Res.</source> <volume>51</volume> (<issue>D1</issue>), <fpage>D587</fpage>&#x2013;<lpage>D592</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac963</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Furumichi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Morishima</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Res.</source> <volume>45</volume> (<issue>D1</issue>), <fpage>D353</fpage>&#x2013;<lpage>D361</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Astragalus polysaccharides attenuates TNF-&#x3b1;-induced insulin resistance via suppression of miR-721 and activation of PPAR-&#x3b3; and PI3K/AKT in 3T3-L1 adipocytes</article-title>. <source>Am. J. Transl. Res.</source> <volume>9</volume>, <fpage>2195</fpage>&#x2013;<lpage>2206</lpage>.</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>C. K.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Research progress of Codonopsis Radix and prediction of its Q-markers</article-title>. <source>Zhongguo Zhong Yao Za Zhi</source> <volume>48</volume> (<issue>8</issue>), <fpage>2020</fpage>&#x2013;<lpage>2040</lpage>. <pub-id pub-id-type="doi">10.19540/j.cnki.cjcmm.20221231.202</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levitt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lifson</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1969</year>). <article-title>Refinement of protein conformations using amacromolecular energy minimization procedure</article-title>. <source>J. Mol.</source> <volume>46</volume> (<issue>2</issue>), <fpage>269</fpage>&#x2013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(69)90421-5</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Network pharmacology approaches for research of Traditional Chinese Medicines</article-title>. <source>Chin. J. Nat. Med.</source> <volume>21</volume> (<issue>5</issue>), <fpage>323</fpage>&#x2013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1016/s1875-5364(23)60429-7</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>A comprehensive electron wavefunction analysis toolbox for chemists, Multiwfn</article-title>. <source>J. Chem. Phys.</source> <volume>161</volume>, <fpage>082503</fpage>. <pub-id pub-id-type="doi">10.1063/5.0216272</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F. W.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Multiwfn: a multifunctional wavefunction analyzer</article-title>. <source>J. Comput. Chem.</source> <volume>33</volume>, <fpage>580</fpage>&#x2013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.22885</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Y. P.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>B. B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Effect of Codonopsis Radix and Polygonati Rhizoma on the regulation of the IRS1/PI3K/AKT signaling pathway in type 2 diabetic mice</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>13</volume>, <fpage>1068555</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.1068555</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doble</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>MacAulay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Drucker</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Woodgett</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Tissue-specific role of glycogen synthase kinase 3&#x3b2; in glucose homeostasis and insulin action</article-title>. <source>Mol. Cell Biol.</source> <volume>28</volume>, <fpage>6314</fpage>&#x2013;<lpage>6328</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.00763-08</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rastelli</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular docking: shifting paradigms in drug discovery</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>18</issue>), <fpage>4331</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20184331</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powell</surname>
<given-names>M. J. D.</given-names>
</name>
</person-group> (<year>1977</year>). <article-title>Restart procedures for the conjugate gradient method</article-title>. <source>Math. Program.</source> <volume>12</volume> (<issue>1</issue>), <fpage>241</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1007/bf01593790</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Advances in computational chemistry-related research</article-title>. <source>Interdiscip. Sci. Lett.</source> <volume>2</volume> (<issue>4</issue>), <fpage>111</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.12677/ISL.2018.24021</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>TCMSP: a database of systems pharmacology for drug discovery from herbal medicines</article-title>. <source>J. Cheminform</source> <volume>6</volume>, <fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-6-13</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Markiel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozier</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res.</source> <volume>13</volume> (<issue>11</issue>), <fpage>2498</fpage>&#x2013;<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Garber</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Role of insulin signaling in maintaining energy homeostasis</article-title>. <source>Endocr. Pract.</source> <volume>14</volume> (<issue>3</issue>), <fpage>373</fpage>&#x2013;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.4158/ep.14.3.373</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherman</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Baseler</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>H. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title>. <source>Nucleic Acids Res.</source> <volume>50</volume> (<issue>W1</issue>), <fpage>W216</fpage>&#x2013;<lpage>W221</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Koutrouli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nastou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mehryary</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hachilif</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title>. <source>Nucleic Acids Res.</source> <volume>51</volume> (<issue>D1</issue>), <fpage>D638</fpage>&#x2013;<lpage>D646</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taha</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Klip</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The insulin signaling pathway</article-title>. <source>J. Membr. Biol.</source> <volume>169</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/pl00005896</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tessaro</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scapozza</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>How &#x27;protein-docking&#x27; translates into the new emerging field of docking small molecules to nucleic acids?</article-title> <source>Molecules</source> <volume>25</volume> (<issue>12</issue>), <fpage>2749</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25122749</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tirado-Rives</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>W. L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Performance of B3LYP density functional methods for a large set of organic molecules</article-title>. <source>J. Chem. Theory Comput.</source> <volume>4</volume> (<issue>2</issue>), <fpage>297</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1021/ct700248k</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Antiatherogenic effects ofkaempferol and rhamnocitrin</article-title>. <source>J. Agric. Food Chem.</source> <volume>55</volume> (<issue>24</issue>), <fpage>9969</fpage>&#x2013;<lpage>9976</lpage>. <pub-id pub-id-type="doi">10.1021/jf0717788</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R. Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F. X.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>An overview on molecular dynamics simulation</article-title>. <source>Adv. Mech.</source> <volume>33</volume> (<issue>1</issue>), <fpage>65</fpage>&#x2013;<lpage>73</lpage>.</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Application of molecular dynamics simulation in biomedicine</article-title>. <source>Chem. Biol. Drug Des.</source> <volume>99</volume> (<issue>5</issue>), <fpage>789</fpage>&#x2013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.14038</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>S. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle, through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway</article-title>. <source>Chin. J. Nat. Med.</source> <volume>14</volume> (<issue>1</issue>), <fpage>48</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.3724/SP.J.1009.2016.00048</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Astragalus polysaccharide alleviates type 2 diabetic rats by reversing the glucose transporters and sweet taste receptors/GLP-1/GLP-1 receptor signaling pathways in the intestine-pancreatic axis</article-title>. <source>J. Funct. Foods</source> <volume>76</volume>, <fpage>104310</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2020.104310</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Musgrave</surname>
<given-names>C. B.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Comparison of DFT methods for molecular orbital eigenvalue calculations</article-title>. <source>J. Phys. Chem. A</source> <volume>111</volume> (<issue>8</issue>), <fpage>1554</fpage>&#x2013;<lpage>1561</lpage>. <pub-id pub-id-type="doi">10.1021/jp061633o</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Edouard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nice</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Oxidative stress and diabetes: antioxidative strategies</article-title>. <source>Front. Med.</source> <volume>14</volume> (<issue>5</issue>), <fpage>583</fpage>&#x2013;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1007/s11684-019-0729-1</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>G. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Expression of PI3-K, PKB and GSK-3&#x3b2; in the skeletal muscle tissue of gestational diabetes mellitus</article-title>. <source>Asian Pac J. Trop. Med.</source> <volume>7</volume>, <fpage>309</fpage>&#x2013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/s1995-7645(14)60045-6</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Molecular calculation theory method and its application in chemical engineering calculation field</article-title>. <source>Comput. Appl. Chem.</source> <volume>21</volume> (<issue>5</issue>), <fpage>764</fpage>&#x2013;<lpage>772</lpage>.</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y. H.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Molecular dynamics simulation and its application in the materials science</article-title>. <source>Mater. Rev.</source> <volume>21</volume> (<issue>4</issue>), <fpage>5</fpage>&#x2013;<lpage>8</lpage>.</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A review of the pharmacological action of Astragalus polysaccharide</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>349</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00349</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>TTD: therapeutic Target Database describing target druggability information</article-title>. <source>Nucleic Acids Res.</source> <volume>52</volume> (<issue>D1</issue>), <fpage>D1465</fpage>&#x2013;<lpage>D1477</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad751</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>